(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 23 October 2003 (23.10.2003)

PCT

(10) International Publication Number WO 2003/087312 A3

- (51) International Patent Classification⁷: C12Q 1/68, 1/02, 1/37, 1/00, C12N 15/09, A01K 39/00
- (21) International Application Number:

PCT/US2003/010539

- (22) International Filing Date: 8 April 2003 (08.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/370,873

8 April 2002 (08.04.2002) US

- (71) Applicant (for all designated States except US): THE JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market Place, Suite 906, Baltimore, MD 21202 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DANG, Chi, V. [US/US]; 217 Upnor Road, Baltimore, MD 21212 (US). WONSEY, Diane [US/US]; 5904A Cross Country Boulevard, Baltimore, MD 21215 (US).


- (74) Agent: KAGAN, Sarah, A.; Banner & Witcoff, Ltd., 1001 G. Street, N.W., Eleventh Floor, Washington, DC 20001-4597 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

[Continued on next page]

(54) Title: INHIBITION OF TUMOR GROWTH VIA PEROXIREDOXIN 3



(57) Abstract: Deregulated expression of the c-Myc transcription factor is found in a wide variety of human tumors. Considerable effort has been devoted to elucidating the molecular program initiated by deregulated c-myc expression because of the significant role in oncogenesis. The primary transforming activity of Myc is thought to arise through transcriptional regulation of numerous target genes. A nuclear c-Myc target gene, PRDX3, which encodes a mitochondrial protein of the peroxiredoxin gene family is discribed. PRDX3 is required for Myc-mediated proliferation, transformation, and apoptosis after glucose withdrawal. Results using mitochondria-specific fluorescent probes demonstrate that PRDX3 is essential for maintaining mitochondrial mass and membrane potential in transformed rat and human cells. These data provide evidence that PRDX3 is a c-Myc target gene required to maintain normal mitochondrial function. Figure (1) shows PRDX3 regulated by c-myc expression.

WO 2003/087312 A3



(88) Date of publication of the international search report: 4 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US03/10539

A. CLASSIFICATION OF SUBJECT MATTER			
IPC(7) : C12Q 1/68, 1/02, 1/37, 1/00; C12N 15/09; A01K 39/00			
US CL : 435/6, 29, 23, 24, 4, 69.2; 424/277.1; 530/300			
According to International Patent Classification (IPC) or to both national classification and IPC			
B. FIELDS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols)			
U.S. : 435/6, 29, 23, 24, 4, 69.2			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields			
searched PATENT LITERATURE			
NON FAIENT LITERATURE			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)			
WEST: tumor cell, nucleotides murine or human PRDX3 cDNA			
C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where a	opropriate, of the relevant passages	Relevant to claim No.
	110 (120 (71 D1 (F) OHE) **	12 4 2002	1 24
Α	US 6,432,671 B1 (FLOHE et al)	13 August 2002, see entire	1-34
	document.		
-			
	<u> </u>		
Further documents are listed in the continuation of Box C. See patent family annex.			
Special categories of cited documents: "T" later document published after the international filing date or priority			
•	ocument defining the general state of the art which is not	date and not in conflict with the appl the principle or theory underlying th	
considered to be of particular relevance			
	rlier document published on or after the international filing date	considered novel or cannot be conside	
	ocument which may throw doubts on priority claim(s) or which is ted to establish the publication date of another citation or other	when the document is taken alone	
	recial reason (as specified)	"Y" document of particular relevance; the considered to involve an inventive	
	ocument referring to an oral disclosure, use, exhibition or other	combined with one or more other suc	documents, such combination
	eans	being obvious to a person skilled in	
	P" document published prior to the international filing date but later "&" document member of the same patent family than the priority date claimed		
Date of the actual completion of the international search Date of mailing of the international search report			
30 SEPTEMBER 2003 28 NOV 2003			
SO SEPTEMBER 2003			
Name and mailing address of the ISA/US Authorized officer (
Commissioner of Patents and Trademarks Authorized officers Authorized officers Authorized officers			
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Authorized officer LOUISE LEARY			
1	Jo. (709) 805 8880	Telephone No. (708) 908 1885	/